LU92702I2 - Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig) - Google Patents
Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig) Download PDFInfo
- Publication number
- LU92702I2 LU92702I2 LU92702C LU92702C LU92702I2 LU 92702 I2 LU92702 I2 LU 92702I2 LU 92702 C LU92702 C LU 92702C LU 92702 C LU92702 C LU 92702C LU 92702 I2 LU92702 I2 LU 92702I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- moventig
- naloxegol
- pharmaceutically acceptable
- acceptable salt
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
- C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
- C08G65/08—Saturated oxiranes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
- C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53012203P | 2003-12-16 | 2003-12-16 | |
PCT/US2004/042661 WO2005058367A2 (fr) | 2003-12-16 | 2004-12-16 | Petites molecules chimiquement modifiees |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92702I2 true LU92702I2 (fr) | 2016-07-29 |
Family
ID=34700098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92702C LU92702I2 (fr) | 2003-12-16 | 2015-04-29 | Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig) |
Country Status (26)
Country | Link |
---|---|
US (2) | US7786133B2 (fr) |
EP (3) | EP1694363B1 (fr) |
JP (1) | JP4991312B2 (fr) |
KR (1) | KR101168620B1 (fr) |
CN (3) | CN1925875A (fr) |
AU (2) | AU2004299138B2 (fr) |
CA (2) | CA2758460C (fr) |
CY (2) | CY1114992T1 (fr) |
DK (1) | DK1694363T3 (fr) |
EA (2) | EA018427B1 (fr) |
ES (3) | ES2733764T3 (fr) |
FR (1) | FR15C0037I2 (fr) |
HK (2) | HK1146645A1 (fr) |
HR (1) | HRP20140361T1 (fr) |
HU (1) | HUS1500026I1 (fr) |
IL (2) | IL176317A (fr) |
LT (1) | LTC1694363I2 (fr) |
LU (1) | LU92702I2 (fr) |
NL (1) | NL300737I2 (fr) |
NZ (3) | NZ583573A (fr) |
PL (1) | PL1694363T3 (fr) |
PT (1) | PT1694363E (fr) |
RS (1) | RS53279B (fr) |
SI (1) | SI1694363T1 (fr) |
WO (1) | WO2005058367A2 (fr) |
ZA (1) | ZA200605763B (fr) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143328A1 (en) * | 2001-08-13 | 2009-06-04 | Mcdonald George | Method of Treating Cancer by Administration of Topical Active Corticosteroids |
CA2463938C (fr) | 2001-10-18 | 2011-08-09 | Nektar Therapeutics Al, Corporation | Conjugues polymeres d'antagonistes opioides |
CA2758460C (fr) | 2003-12-16 | 2014-09-23 | Nektar Therapeutics | Methodes de preparation de compositions de reactifs oligo (ethylene glycol) monodisperses |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
TWI515007B (zh) | 2006-01-05 | 2016-01-01 | 美國猶他大學研究基金會 | 改善以神經系統為標的之藥劑之性質之方法及組合物 |
DK1988910T3 (en) | 2006-02-28 | 2018-01-22 | Kodiak Sciences Inc | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof |
NZ572252A (en) * | 2006-04-21 | 2011-09-30 | Nektar Therapeutics | Stereoselective reduction of a morphinone |
MX2009004965A (es) * | 2006-11-07 | 2009-06-05 | Nektar Therapeutics Al Corp | Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides. |
KR100829890B1 (ko) | 2007-02-08 | 2008-05-16 | 주식회사 바이오폴리메드 | 신규한 레티놀 유도체, 이의 제조방법 및 이를 포함하는주름 개선용 화장료 조성물 |
US8389759B2 (en) | 2007-03-12 | 2013-03-05 | Nektar Therapeutics | Oligomer-anticholinergic agent conjugates |
WO2008112289A2 (fr) * | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Conjugués d'oligomère-inhibiteur de protéase |
US20100184989A1 (en) * | 2007-03-12 | 2010-07-22 | Nektar Therapeutics | De Novo Synthesis of Conjugates |
AU2014200906B2 (en) * | 2007-03-12 | 2016-07-07 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
EP2121031B1 (fr) * | 2007-03-12 | 2013-10-16 | Nektar Therapeutics | Conjugués d'oligomère antihistaminique |
KR101568428B1 (ko) | 2007-03-12 | 2015-11-11 | 넥타르 테라퓨틱스 | 올리고머―오피오이드 효능제 컨주게이트 |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
WO2008112287A1 (fr) * | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Conjugués d'oligomère bêtabloquant |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
US8748648B2 (en) | 2007-09-06 | 2014-06-10 | Nektar Therapeutics | Oligomer-calcium channel blocker conjugates |
US8741858B2 (en) | 2007-09-21 | 2014-06-03 | Zhongxu Ren | Oligomer-nucleoside phosphate conjugates |
US8796248B2 (en) * | 2007-10-05 | 2014-08-05 | Nektar Therapeutics | Oligomer-corticosteroid conjugates |
WO2009054916A2 (fr) * | 2007-10-19 | 2009-04-30 | Nektar Therapeutics Al, Corporation | Conjugués d'oligomère de lidocaïne et leurs dérivés |
US8853247B2 (en) * | 2007-11-02 | 2014-10-07 | Nektar Therapeutics | Oligomer-nitroimidazole anti-infective conjugates |
WO2009067175A2 (fr) * | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Conjugués oligomère-dantrolène et composés associés |
MX2010005813A (es) * | 2007-11-28 | 2010-06-15 | Nektar Therapeutics | Conjugados oligomero-triciclicos. |
US20110009446A1 (en) * | 2008-01-11 | 2011-01-13 | Nektar Therapeutics | Oligomer-guanidine class conjugates |
US8685979B2 (en) | 2008-01-25 | 2014-04-01 | Nektar Therapeutics | Oligomer-diarylpiperazine conjugates |
US8829043B2 (en) | 2008-02-08 | 2014-09-09 | Nektar Therapeutics | Oligome-cannabinoid conjugates |
WO2009105258A1 (fr) | 2008-02-22 | 2009-08-27 | Nektar Therapeutics Al, Corporation | Conjugués oligomères de nucléosides hétéropentacycliques |
US9006219B2 (en) | 2008-03-12 | 2015-04-14 | Nektar Therapeutics | Oligomer-foscarnet conjugates |
US9095620B2 (en) * | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
US20110059921A1 (en) * | 2008-03-27 | 2011-03-10 | Ektar Therapeutics | Oligomer-Nitrogenous Base Conjugates |
CN101998866A (zh) * | 2008-04-11 | 2011-03-30 | 尼克塔治疗公司 | 低聚物-芳氧基-取代的丙胺共轭物 |
US9095621B2 (en) * | 2008-04-25 | 2015-08-04 | Nektar Therapeutics | Oligome-bis-chromonyl compound conjugates |
CN104524590B (zh) | 2008-04-30 | 2019-06-21 | 伊缪诺金公司 | 交联剂和它们的用途 |
BRPI0912219A2 (pt) * | 2008-05-07 | 2015-10-06 | Nektar Therapeutics | método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente. |
WO2009151590A2 (fr) * | 2008-06-09 | 2009-12-17 | Nektar Therapeutics | Procédés de traitement de métaboliseurs alternatifs de cyp2d6 |
US20110237614A1 (en) * | 2008-09-16 | 2011-09-29 | Nektar Therapeutics | Pegylated Opioids with Low Potential for Abuse |
JP2012502906A (ja) * | 2008-09-17 | 2012-02-02 | ネクター セラピューティックス | オリゴマー−プロテアーゼ阻害剤コンジュゲート |
WO2010033219A2 (fr) | 2008-09-17 | 2010-03-25 | Nektar Therapeutics | Inhibiteurs de protéases ayant des propriétés améliorées |
CA2749126C (fr) * | 2009-01-28 | 2017-08-22 | Nektar Therapeutics | Conjugues oligomere-phenothiazine |
WO2010099200A1 (fr) | 2009-02-24 | 2010-09-02 | Nektar Therapeutics | Conjugués oligomère-acides aminés |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
US8816077B2 (en) | 2009-04-17 | 2014-08-26 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
WO2010132693A2 (fr) | 2009-05-13 | 2010-11-18 | Nektar Therapeutics | Composés pyrrolidine contenant un oligomère |
EP2430003B1 (fr) * | 2009-05-13 | 2019-02-27 | Nektar Therapeutics | Composés triazine aromatiques substitués contenant un oligomère |
SI2437790T1 (sl) | 2009-06-03 | 2019-07-31 | Immunogen, Inc. | Konjugacijske metode |
JP2012530069A (ja) | 2009-06-12 | 2012-11-29 | ネクター セラピューティックス | プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体 |
CA2768392C (fr) | 2009-07-21 | 2018-04-17 | Nektar Therapeutics | Conjugues oligomeres-agonistes opioides |
CN105503889B (zh) * | 2009-07-21 | 2019-12-24 | 尼克塔治疗公司 | 低聚物-阿片样激动剂轭合物 |
AU2010315805B2 (en) * | 2009-09-29 | 2015-09-17 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
US20130023553A1 (en) | 2010-01-12 | 2013-01-24 | Nektar Therapeutics | Pegylated opioids with low potential for abuse and side effects |
WO2011091050A1 (fr) | 2010-01-19 | 2011-07-28 | Nektar Therapeutics | Conjugués oligomères-tricycliques |
WO2011103559A1 (fr) * | 2010-02-22 | 2011-08-25 | Nektar Therapeutics | Composés diaromatiques substitués modifiés par un oligomère |
US20160015656A2 (en) * | 2010-08-05 | 2016-01-21 | Nitto Denko Corporation | Composition for regenerating normal tissue from fibrotic tissue |
US9012469B2 (en) * | 2010-09-30 | 2015-04-21 | Astrazeneca Ab | Crystalline naloxol-peg conjugate |
US9226971B2 (en) | 2010-10-15 | 2016-01-05 | Nektar Therapeutics | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides |
US9090535B2 (en) | 2010-12-10 | 2015-07-28 | Nektar Therapeutics | Hydroxylated tricyclic compounds |
WO2012082995A1 (fr) | 2010-12-15 | 2012-06-21 | Nektar Therapeutics | Composés d'hydantoïne contenant un oligomère |
AU2011343822B2 (en) * | 2010-12-15 | 2017-06-29 | Neuroadjuvants, Inc. | Neuropeptide analogs, compositions, and methods for treating pain |
WO2012083153A1 (fr) | 2010-12-16 | 2012-06-21 | Nektar Therapeutics | Composés comprenant une fraction apremilast et contenant un oligomère |
US9943605B2 (en) | 2010-12-23 | 2018-04-17 | Nektar Therapeutics | Polymer-semaxanib moiety conjugates |
US10525054B2 (en) | 2011-11-07 | 2020-01-07 | Inheris Biopharma, Inc. | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound |
CN103906522B (zh) | 2011-11-07 | 2017-04-12 | 尼克塔治疗公司 | 阿片激动剂化合物和止痛化合物的组合物、剂型以及共给药 |
CN103289075B (zh) * | 2012-02-22 | 2016-01-20 | 天津键凯科技有限公司 | 聚乙二醇与纳洛酮的结合物及其药物组合物和应用 |
JP6265998B2 (ja) | 2012-09-17 | 2018-01-24 | ネクター セラピューティクス | オリゴマー含有ベンズアミド系化合物 |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
US9789198B2 (en) * | 2013-05-31 | 2017-10-17 | Jenkem Technology Co., Ltd. (Tianjin) | Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity |
CN104208715B (zh) | 2013-05-31 | 2016-12-28 | 天津键凯科技有限公司 | 具有提高的药物生物活性的低分子量聚乙二醇药物结合物 |
JP6577943B2 (ja) | 2013-06-28 | 2019-09-18 | ネクター セラピューティクス | κオピオイド作動薬及びその使用 |
SI3041513T1 (sl) | 2013-09-08 | 2020-11-30 | Kodiak Sciences Inc. | Zwitterionski polimerni konjugati faktorja VIII |
EP3074379B1 (fr) | 2013-11-27 | 2019-06-26 | Nektar Therapeutics (India) Pvt. Ltd. | Agonistes opioïdes et leurs utilisations |
CA2875384A1 (fr) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Compositions de naxlone intranasales et procedes de fabrication et d'utilisation de celles-ci |
CN114262344A (zh) | 2014-02-28 | 2022-04-01 | 杭州多禧生物科技有限公司 | 带电荷链接体及其在共轭反应上的应用 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2016004321A1 (fr) * | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Composés pour traiter une infection à biofilm |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
GB2545368B (en) * | 2014-10-20 | 2021-04-21 | Elysium Therapeutics Inc | Diversion-resistant opioid formulations |
CN104473927A (zh) * | 2014-12-05 | 2015-04-01 | 北京键凯科技有限公司 | 一种聚乙二醇与药物分子结合物及其制备方法 |
US10322107B2 (en) | 2014-12-23 | 2019-06-18 | Nektar Therapeutics | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor |
US10766864B2 (en) | 2015-05-08 | 2020-09-08 | Nektar Therapeutics | Morphinan derivatives for the treatment of neuropathic pain |
CA2991973C (fr) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Lieurs de pontage pour la conjugaison d'une molecule de liaison cellulaire |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
CN107033154B (zh) * | 2016-02-02 | 2020-02-04 | 上海瀚迈生物医药科技有限公司 | 阿片受体拮抗剂缀合物及其应用 |
CN107033155B (zh) * | 2016-02-04 | 2019-04-26 | 国药集团国瑞药业有限公司 | 一种吗啡酮类化合物的立体选择性还原方法 |
EP3228307A1 (fr) | 2016-04-05 | 2017-10-11 | Sandoz Ag | Solid dispersion contenant des antagonistes opioides |
KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
US11077103B2 (en) | 2016-11-23 | 2021-08-03 | Aurobindo Pharma Ltd. | Naloxegol oxalate and solid dispersion thereof |
US11419946B2 (en) | 2017-03-30 | 2022-08-23 | Nof Corporation | Heterobifunctional monodispersed polyethylene glycol and conjugate using same |
EP3604384B1 (fr) | 2017-03-30 | 2021-09-08 | NOF Corporation | Dérivé de polymère hydrophile comportant un coupleur acétal auto-immolable et composite l'utilisant |
CN109134479A (zh) * | 2017-06-27 | 2019-01-04 | 石家庄蒎格医药科技有限公司 | 结晶聚乙二醇纳洛酮草酸盐及制备方法 |
WO2019058387A1 (fr) * | 2017-09-19 | 2019-03-28 | Msn Laboratories Private Limited, R&D Center | Procédé amélioré de préparation de (5α,6α)-17-allyl-6-(2,5,8,11,14,17,20-heptaoxadocosan-22-yloxy) -4,5-époxymorphinane-3,14-diol et de ses sels pharmaceutiquement acceptables |
JP7204078B2 (ja) | 2018-03-13 | 2023-01-16 | 日油株式会社 | 主鎖および側鎖に単分散ポリエチレングリコールを有するヘテロ二官能性化合物 |
WO2021060439A1 (fr) | 2019-09-26 | 2021-04-01 | 日油株式会社 | Polyéthylène glycol monodispersé hétérobifonctionnel ayant un lieur peptidique |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
CN113827576B (zh) * | 2021-11-17 | 2023-08-01 | 北京尚修堂医药科技有限公司 | 一种活性成分为草酸纳洛解的药物组合物及制备方法 |
WO2024134619A1 (fr) | 2022-12-23 | 2024-06-27 | Sintalica S.R.L. | Composés de tryptamine non hallucinogènes, préparation, compositions pharmaceutiques et leurs utilisations |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4223163A (en) * | 1976-12-10 | 1980-09-16 | The Procter & Gamble Company | Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution |
US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
FR2514644A1 (fr) | 1981-10-19 | 1983-04-22 | Sanofi Sa | Composition pharmaceutique a action antagoniste peripherique des opiaces |
US4587046A (en) * | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4806556A (en) * | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4730048A (en) * | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4861781A (en) * | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JPH01207320A (ja) | 1988-02-15 | 1989-08-21 | Daicel Chem Ind Ltd | 芳香族ポリエーテルの製造方法 |
IT1216687B (it) * | 1988-04-01 | 1990-03-08 | Boehringer Biochemia Srl | Complessi di platino (ii), loro preparazione e impiego come antitumorali. |
US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
ES2104566T3 (es) * | 1989-03-10 | 1997-10-16 | Hoffmann La Roche | Reactivos para la determinacion de drogas. |
US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
JPH0383914A (ja) * | 1989-08-18 | 1991-04-09 | W R Grace & Co | ドラッグキャリアー |
DE3937797A1 (de) * | 1989-11-14 | 1991-05-16 | Basf Ag | Verfahren zur herstellung von polyetherglykolen |
US5130126A (en) * | 1990-07-09 | 1992-07-14 | Nippon Oil & Fats Co., Ltd. | Polymer-drug conjugate and a method of producing it |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
JP2829794B2 (ja) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | 徐放性経口投与型プラノプロフェン製剤 |
US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
US5250542A (en) * | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
WO1993024476A1 (fr) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Vehicules polymeres solubles dans l'eau servant a la liberation de medicaments |
GB9316895D0 (en) * | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
EP0599303A3 (fr) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Conjugués peptidiques |
US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5321095A (en) * | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
ES2122261T3 (es) * | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester. |
AU7113594A (en) * | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5670477A (en) * | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
AU712713B2 (en) | 1995-06-07 | 1999-11-11 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
AU730969B2 (en) | 1995-10-19 | 2001-03-22 | University Of Washington | Discrete-length polyethylene glycols |
US5639705A (en) * | 1996-01-19 | 1997-06-17 | Arco Chemical Technology, L.P. | Double metal cyanide catalysts and methods for making them |
PT914097E (pt) * | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
US5856369A (en) | 1996-07-30 | 1999-01-05 | Osi Specialties, Inc. | Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts |
DE19632440A1 (de) | 1996-08-12 | 1998-02-19 | Basf Ag | Verfahren zur Herstellung von aus Polykationen aufgebauten, geformten Mischhydroxiden |
US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
DE19651551C2 (de) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
US6011008A (en) * | 1997-01-08 | 2000-01-04 | Yissum Research Developement Company Of The Hebrew University Of Jerusalem | Conjugates of biologically active substances |
GB9703044D0 (en) * | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US5972954A (en) * | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
EP1037649B1 (fr) * | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
WO1999045964A1 (fr) | 1998-03-12 | 1999-09-16 | Shearwater Polymers, Incorporated | Derives de poly(ethylene glycol) avec groupes reactifs proximaux |
WO1999050240A1 (fr) * | 1998-03-30 | 1999-10-07 | Lg Chemical Ltd. | Derives de retinamide polyethoxyles et leur procede de preparation |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
EP0995757A3 (fr) * | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibiteurs bivalentes de la proteasome |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
KR100345214B1 (ko) | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
US6380405B1 (en) * | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
KR100702878B1 (ko) * | 1999-10-29 | 2007-04-04 | 넥타르 테라퓨틱스 | 개선된 분산성을 갖는 건조 분말 조성물 |
JP4861586B2 (ja) * | 1999-12-22 | 2012-01-25 | ネクター セラピューティックス | 水溶性ポリマーの立体的に妨害される誘導体 |
US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
WO2001062299A2 (fr) | 2000-02-28 | 2001-08-30 | Shearwater Corporation | Conjugues polymeres hydrosolubles d'acide artelinique |
CA2403252A1 (fr) | 2000-03-15 | 2001-09-20 | Wolfgang Sadee | Antagonistes neutres et utilisation de ces derniers dans le traitement de l'abus des drogues |
IL154536A0 (en) * | 2000-08-29 | 2003-09-17 | Nobex Corp | Immunoregulatory compounds and derivatives and methods of treating diseases therewith |
US7829074B2 (en) * | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
JP2004514701A (ja) | 2000-11-30 | 2004-05-20 | ネクター セラピューティクス エーエル,コーポレイション | トリアジン誘導体の水溶性ポリマー複合体 |
PT1349855E (pt) * | 2000-12-22 | 2006-12-29 | Smithkline Beecham Plc | Sal misilato de 5-{4-[2-(n-metil-n-(2-piridil)amino)etoxi]benzil}tiazolidino-2, 4-diona |
CA2437989A1 (fr) * | 2001-02-20 | 2002-08-29 | Enzon, Inc. | Lieurs polymeres a terminaisons ramifiees, et conjugues polymeres en contenant |
US20020169125A1 (en) * | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6756354B2 (en) * | 2001-09-05 | 2004-06-29 | Deanna Jean Nelson | Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates |
CA2463938C (fr) * | 2001-10-18 | 2011-08-09 | Nektar Therapeutics Al, Corporation | Conjugues polymeres d'antagonistes opioides |
EP1441772A2 (fr) | 2001-10-29 | 2004-08-04 | Nektar Therapeutics Al, Corporation | Conjugues polymeres d'inhibiteurs de proteine kinease c |
ATE359829T1 (de) * | 2001-10-30 | 2007-05-15 | Nektar Therapeutics Al Corp | Wasserlösliche polymerkonjugate von retinoesäure |
EP1501352B1 (fr) | 2001-12-14 | 2015-02-18 | The University Of Wyoming | Liberation controlee de l'oxycodone |
EP2316468A1 (fr) | 2002-02-22 | 2011-05-04 | Shire LLC | Système de distribution et méthodes de protection et d'administration de dextroamphetamine |
WO2004043396A2 (fr) | 2002-11-09 | 2004-05-27 | Nobex Corporation | Promedicaments contenant du carbamate modifie et methodes de synthese de ces derniers |
JP2006520392A (ja) * | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法 |
GB0317815D0 (en) * | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
US7335751B2 (en) | 2003-08-01 | 2008-02-26 | Biocon Limited | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
CA2547140A1 (fr) * | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Erythropoietine glycopegylee |
CA2758460C (fr) | 2003-12-16 | 2014-09-23 | Nektar Therapeutics | Methodes de preparation de compositions de reactifs oligo (ethylene glycol) monodisperses |
NZ572252A (en) * | 2006-04-21 | 2011-09-30 | Nektar Therapeutics | Stereoselective reduction of a morphinone |
-
2004
- 2004-12-16 CA CA2758460A patent/CA2758460C/fr active Active
- 2004-12-16 CN CNA2004800417476A patent/CN1925875A/zh active Pending
- 2004-12-16 DK DK04814802.7T patent/DK1694363T3/en active
- 2004-12-16 KR KR1020067014260A patent/KR101168620B1/ko active IP Right Grant
- 2004-12-16 CN CN201210398264.8A patent/CN102895666B/zh active Active
- 2004-12-16 AU AU2004299138A patent/AU2004299138B2/en active Active
- 2004-12-16 EA EA201000994A patent/EA018427B1/ru unknown
- 2004-12-16 RS RS20140185A patent/RS53279B/en unknown
- 2004-12-16 PL PL04814802T patent/PL1694363T3/pl unknown
- 2004-12-16 US US11/015,196 patent/US7786133B2/en active Active
- 2004-12-16 ES ES12192296T patent/ES2733764T3/es active Active
- 2004-12-16 SI SI200432133T patent/SI1694363T1/sl unknown
- 2004-12-16 CN CN201010150631.3A patent/CN101805343B/zh active Active
- 2004-12-16 JP JP2006545533A patent/JP4991312B2/ja active Active
- 2004-12-16 EP EP04814802.7A patent/EP1694363B1/fr active Active
- 2004-12-16 WO PCT/US2004/042661 patent/WO2005058367A2/fr active Application Filing
- 2004-12-16 EA EA200601167A patent/EA015333B1/ru unknown
- 2004-12-16 PT PT48148027T patent/PT1694363E/pt unknown
- 2004-12-16 ES ES15156167T patent/ES2817799T3/es active Active
- 2004-12-16 EP EP15156167.7A patent/EP2905033B1/fr active Active
- 2004-12-16 CA CA2549730A patent/CA2549730C/fr active Active
- 2004-12-16 NZ NZ583573A patent/NZ583573A/en unknown
- 2004-12-16 NZ NZ594834A patent/NZ594834A/xx unknown
- 2004-12-16 ES ES04814802.7T patent/ES2445585T3/es active Active
- 2004-12-16 NZ NZ548529A patent/NZ548529A/en unknown
- 2004-12-16 EP EP12192296.7A patent/EP2604282B1/fr active Active
-
2006
- 2006-06-15 IL IL176317A patent/IL176317A/en active Protection Beyond IP Right Term
- 2006-07-12 ZA ZA200605763A patent/ZA200605763B/xx unknown
-
2010
- 2010-06-02 AU AU2010202277A patent/AU2010202277B2/en active Active
- 2010-06-24 US US12/822,935 patent/US8034825B2/en active Active
-
2011
- 2011-01-26 HK HK11100783.8A patent/HK1146645A1/xx unknown
-
2013
- 2013-11-19 IL IL229509A patent/IL229509A/en active IP Right Grant
-
2014
- 2014-03-24 CY CY20141100226T patent/CY1114992T1/el unknown
- 2014-04-16 HR HRP20140361TT patent/HRP20140361T1/hr unknown
-
2015
- 2015-04-29 HU HUS1500026C patent/HUS1500026I1/hu unknown
- 2015-04-29 LU LU92702C patent/LU92702I2/fr unknown
- 2015-05-08 NL NL300737C patent/NL300737I2/nl unknown
- 2015-05-15 LT LTPA2015019C patent/LTC1694363I2/lt unknown
- 2015-05-18 CY CY2015019C patent/CY2015019I2/el unknown
- 2015-05-19 FR FR15C0037C patent/FR15C0037I2/fr active Active
- 2015-11-12 HK HK15111168.6A patent/HK1210418A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92702I2 (fr) | Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig) | |
LU93320I2 (fr) | Everolimus ou un sel pharmaceutiquement acceptable de celui-ci | |
LU93327I2 (fr) | Opicapone ou un sel pharmaceutiquement acceptable de celui-ci | |
LU92890I2 (fr) | Panobinstat ou un sel pharmaceutiquement acceptable, ou un dérivé de celui-ci (farydak) | |
LU92684I2 (fr) | Fidaxomicine ou son sel pharmaceutiquement acceptable | |
LU93266I2 (fr) | Sélexipag ou un sel de celui-ci | |
LU92439I2 (fr) | Vilanterol ou un sel ou un solvate de celui-ci | |
LU92446I2 (fr) | Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium | |
NO2015016I1 (no) | Vorapaxar, eller et farmasøytisk akseptabelt salt eller solvat derav | |
LU92701I2 (fr) | Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive | |
EG23424A (en) | Fungicidal azo-carboxamide derivatives. | |
LU92512I2 (fr) | Afoxolaner, ou un oxyde nitrique de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci | |
ATE406162T1 (de) | Pramipexol-tablette mit verzögerter wirkstoffabgabe | |
EP1663113A4 (fr) | Sulfonamides substitues | |
DE60317391D1 (de) | Verbinder | |
ATE325420T1 (de) | Übertrager | |
DE60301239D1 (de) | Verbinder | |
DE60315937D1 (de) | Verbinder | |
DE60208885D1 (de) | Verbinder | |
DE60223352D1 (de) | Verbinder | |
FI5838U1 (fi) | Kuori | |
FR2856663B1 (fr) | Capsule de bouchage a vis amelioree | |
DE50304722D1 (de) | Fungizide Wirkstoffkombinationen | |
DE10301279B8 (de) | Verbinder | |
DE60218623D1 (de) | Verbinder |